Colinz Laboratories Limited announced its unaudited financial results for the quarter ended December 31, 2025, demonstrating robust growth in profitability. The pharmaceutical formulations manufacturer reported a significant 56.8% year-on-year increase in net profit, reaching ₹8.36 crore compared to ₹5.33 crore in the corresponding quarter of the previous year.

Financial Performance Overview

The company's quarterly performance showed mixed results across different parameters. Revenue from operations stood at ₹143.41 crore for Q3FY26, representing a decline from ₹146.65 crore in Q3FY24. However, the addition of other income of ₹7.54 crore brought total income to ₹150.95 crore for the quarter.

Operational Efficiency and Cost Management

The company demonstrated improved operational efficiency during the quarter. Total expenses decreased to ₹138.34 crore from ₹144.06 crore in the corresponding quarter last year. Key expense categories showed varied performance, with employee benefit expenses declining to ₹58.42 crore from ₹68.70 crore year-on-year.

Profit before tax reached ₹12.61 crore, marking a 22.1% increase from ₹10.33 crore in Q3FY24. The company's tax provision for the quarter stood at ₹4.25 crore compared to ₹5.00 crore in the previous year.

Nine-Month Performance Analysis

For the nine months ended December 31, 2025, Colinz Laboratories maintained steady performance with net profit at ₹34.33 crore, marginally lower than ₹34.62 crore in the corresponding period last year. Revenue from operations for the nine-month period totaled ₹438.82 crore compared to ₹507.63 crore in the previous year.

Earnings Per Share and Other Comprehensive Income

The company's earnings per share (EPS) for Q3FY26 improved to ₹0.33 from ₹0.21 in the corresponding quarter last year. For the nine-month period, EPS remained relatively stable at ₹1.36 compared to ₹1.37 in the previous year.

A notable highlight was the significant improvement in other comprehensive income, which reached ₹7.93 crore in Q3FY26 compared to a negative ₹12.11 crore in Q3FY24. This improvement was primarily driven by changes in fair value of investment in equity instruments.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on January 24, 2026. The meeting commenced at 3:30 PM and concluded at 6:15 PM. The results have been audited by Vora & Associates, Chartered Accountants, who issued an unqualified audit opinion.

Colinz Laboratories operates primarily in the pharmaceutical formulations manufacturing business with no other reportable segments. The company's results are available on the BSE website and the company's official website as per SEBI regulations.

Colinz Laboratories Limited has filed an official disclosure with the Bombay Stock Exchange regarding the transmission of a significant shareholding following the demise of one of its promoters. The pharmaceutical company submitted the regulatory disclosure under Regulation 7(2)(a) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, along with Form C documentation.

Share Transmission Details

The transmission involves 8,67,750 equity shares, representing 34.45% of the company's paid-up equity share capital. These shares belonged to the late Dr. Mani L.S., who was a promoter of the company. Following his demise, the shares have been transmitted to his nominee Mrs. Vijaya Mani, who is also a member of the promoter and promoter group and the wife of the late Dr. Mani L.S.

Shareholding Pattern Changes

The transmission has resulted in a significant change in Mrs. Vijaya Mani's individual shareholding pattern. Her total holding has increased substantially following the inheritance of her late husband's shares, making her the largest individual shareholder in the company.

Regulatory Compliance Framework

The company has filed the disclosure in compliance with SEBI's Prohibition of Insider Trading Regulations, specifically under Regulation 7(2)(a). The submission includes Form C documentation detailing the acquisition of shares through transmission. The company emphasized that this acquisition has been effected through transmission of shares and there is no change in the overall promoter group shareholding.

Company Capital Structure

The company's equity share capital remains unchanged following the transmission. Colinz Laboratories operates in the pharmaceutical sector and is listed on the Bombay Stock Exchange with the code 531210.

The transmission maintains the same total holding of the promoter and promoter group both prior to and post the transmission, ensuring continuity in the company's ownership structure while complying with all regulatory requirements for substantial shareholding changes.